Should you buy Humana stock now?
The technical signal for Humana is currently NEUTRAL. Humana trades at $356.77 as of 8/6/2026. The overall technical signal is: Hold. The technical analysis shows the following: MACD is negative (bearish trend) at -2.189 with falling momentum (signal: 3.346); RSI is at 42.7 (neutral zone); the stock is in a short-term downtrend (price below the 20-day average); the analyst price target of $407.83 points to 14.3% upside. This is a technical observation based on current data, not investment advice.
What is the price target for Humana stock?
The average analyst price target for Humana is $407.83. The current price is $356.77, which gives an upside of 14.3%. Based on this, the stock is considered undervalued. The fair value range (±10% of the price target) is between $367.05 and $448.61.
Is Humana a dividend stock?
Yes, Humana is a dividend stock with a dividend yield of 0.95%. The latest dividend was $0.89 per share. The latest ex-dividend date (traded without the dividend) was 6/26/2026. The payout ratio is 20.6%, which is considered sustainable. The next dividend payment is scheduled for 7/31/2026.
When does Humana pay a dividend in 2026?
Humana pays its next dividend on 7/31/2026. The latest dividend was $0.89 per share with an ex-dividend date of 6/26/2026. The dividend yield is 0.95%. The payout ratio of 20.6% points to a sustainable dividend with room to grow.
What is the risk of Humana stock?
Humana is rated as a stock with high risk. the annual standard deviation is 48.4%, which classifies the stock as high risk.
Is Humana overvalued?
No, Humana is considered undervalued based on the analyst price target (14.3% upside). Humana has the following valuation ratios: a P/E ratio of 34.2 (highly valued), a P/S ratio of 0.3, a P/B ratio of 2.3. The analyst price target suggests that the stock is undervalued by 14.3%.
Is Humana overbought?
No, Humana is not overbought. RSI is at 42.7 (neutral zone). The technical indicators show: RSI is at 42.7 (neutral zone between 30-70), which signals neither overbought nor oversold. In addition, the price is 7.9% below the 20-day average (short-term downtrend). In addition, MACD is negative with falling momentum (bearish).
When is the next Humana earnings report?
The date of the next earnings report for Humana has not been published yet. Check the company's investor calendar for updates.
Is Humana shorted?
Yes, Humana is shorted with 4.0% of the free float sold short. This is a moderate level of short selling, within the normal range for most stocks. Data is updated daily based on official filings with the SEC.
Are insiders buying Humana stock?
No, insiders are not buying Humana shares – they are net sellers. Across the last 20 reported transactions, the split is 1 purchases and 19 sales, with a net 9,902,979 $ sold. Active sellers include Shetty Sanjay K, Ventura Joseph C, Renaudin George II and others. Insider selling can have several explanations (e.g. planned 10b5-1 sales, portfolio diversification or taxes), but sustained selling by several insiders is worth watching closely.
Is Humana a good stock?
Based on our total score, Humana is rated as a good stock with a total score of 62 out of 100. The stock scores above average on value, quality and momentum – it is among the top 38% in our database. The score is made up of Value: 64/100, Quality: 38/100, Momentum: 85/100. In addition: analysts see 14.3% upside to the price target; a dividend of 0.95%; technical signal: Hold. Whether Humana is a good investment depends on your time horizon, risk profile and portfolio. This is a data-driven observation, not investment advice.
What is the outlook for Humana stock?
The outlook for Humana based on current data: the average analyst price target is $407.83 (+14.3%); the P/E ratio is 34.2 (high – the market expects growth). Keep in mind that stock prices are affected by many factors, including earnings reports, the economy and market sentiment. Past returns are no guarantee of future returns.
Why is Humana stock falling?
Humana is falling right now. The technical indicators show: the price is 7.9% below the 20-day average; MACD is negative with falling momentum (bearish signal); insiders have mostly been selling the stock recently. For the latest context, see our technical analysis, insider section and news overview above.
How high can Humana go?
The average analyst price target for Humana is $407.83, which corresponds to a potential gain of 14.3% from the current price of $356.77. Keep in mind that price targets are estimates, not guarantees. Actual price moves depend on earnings, market conditions and unexpected events.
How low can Humana fall?
We lack enough history to give a specific floor for Humana. Remember: past price swings are no guarantee for the future — a stock can fall further than the last 52 weeks suggest, especially on profit warnings, sector crises or a market crash. Use stop-loss orders and spread your portfolio to limit losses in single stocks.
What does Humana do?
Humana Inc. provides medical and specialty insurance products in the United States. It operates in two segments, Insurance and CenterWell. The Insurance segment offers individual Medicare Advantage products, including health insurance benefits, including wellness programs, chr... The company belongs to the Sundhed sector, more specifically the Healthcare Plans industry, is headquartered in USA, and is traded on the USA Stocks. See the key figures, earnings history and price development above to evaluate Humana as an investment.
Did Humana raise or lower its guidance?
Over the last 60 days we have not registered a guidance raise or cut from Humana. The company can still adjust its guidance at quarterly reports or between reports — see the earnings history and the news overview above.
Is Humana making money or losing money?
Yes, Humana is making money, not losing it. The company has a profit margin (the share of revenue left over as profit) of 0.9% — which is modest. The operating margin (profit before interest and taxes) is 3.5%. At a P/E ratio of 34.2, you currently pay 34.2 dollars for every dollar of the company's annual earnings. A consistently profitable company is usually more resilient than growth stocks that are not yet making money.
Can Humana go bankrupt?
The bankruptcy risk of Humana is rated as low. Altman Z2 (a model for assessing financial distress) is 4.52 — that places the company in the healthy zone. The company has a healthy balance sheet with limited debt relative to earnings and assets. The Piotroski score (financial health 0-9, higher is better) is 6 — which is average. Debt relative to equity is 182% (high). Remember: models like Altman Z2 are statistical — unexpected shocks (fraud, a sector collapse, lawsuits) can always happen. Spread your portfolio.
Does Humana have a lot of debt?
Yes, Humana has elevated debt relative to equity. The debt-to-equity ratio (D/E — interest-bearing debt to equity) is 182%. For the sundhed sector, anything above 150% counts as elevated — that raises the financial risk, especially if interest rates rise or earnings fall. Note: D/E levels are highly sector-specific — a bank at 300% debt is normal, a tech stock at 300% is extremely leveraged. Always compare with similar companies in the same sector. Can Humana service its debt? Can service its debt without problems — the interest coverage ratio (how many times earnings can cover interest payments) is 5.8x, and net debt equals 2.1 years of earnings (EBITDA).
